Quest Partners LLC Acquires 3,044 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Quest Partners LLC grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 674.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,495 shares of the company’s stock after purchasing an additional 3,044 shares during the period. Quest Partners LLC’s holdings in Neurocrine Biosciences were worth $403,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Renaissance Technologies LLC grew its position in Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock valued at $339,790,000 after acquiring an additional 216,500 shares during the last quarter. AQR Capital Management LLC increased its position in Neurocrine Biosciences by 23.0% during the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after purchasing an additional 228,444 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Neurocrine Biosciences by 1.4% in the second quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company’s stock valued at $128,639,000 after buying an additional 13,069 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Neurocrine Biosciences by 40.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock valued at $97,828,000 after buying an additional 203,934 shares in the last quarter. Finally, 1832 Asset Management L.P. grew its stake in shares of Neurocrine Biosciences by 1,370.7% during the second quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock worth $74,507,000 after buying an additional 504,400 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $125.65 on Monday. Neurocrine Biosciences, Inc. has a one year low of $110.52 and a one year high of $157.98. The company has a market cap of $12.72 billion, a PE ratio of 33.69 and a beta of 0.35. The stock has a 50-day moving average of $118.62 and a 200-day moving average of $131.94.

Analyst Ratings Changes

Several equities research analysts recently weighed in on NBIX shares. Citigroup raised their price objective on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. Royal Bank of Canada cut their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. Guggenheim upped their price objective on Neurocrine Biosciences from $170.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. HC Wainwright reiterated a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 1st. Finally, Raymond James reissued an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Five analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.